Infixion Bioscience

Executive Summary

Infixion Bioscience is a Boston-based private biotech focused on developing disease-modifying therapies for Neurofibromatosis Type 1 (NF1). NF1 is caused by a lack of functional neurofibromin protein, leading to tumor growth and other clinical manifestations. The company aims to address the root cause by restoring neurofibromin function, potentially preventing disease progression across the spectrum of NF1 symptoms. Founded in 2021, Infixion is leveraging drug discovery platforms to identify small molecules and biologics that can restore neurofibromin activity. While the company is still in preclinical stages, its approach targets a significant unmet need with no approved disease-modifying therapies for NF1. The market opportunity is substantial, given NF1 affects approximately 1 in 3,000 individuals worldwide. Infixion's scientific strategy and experienced leadership team position it well to advance its pipeline toward clinical development.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Announcement70% success
• Q4 2026Lead Candidate Nomination60% success
• H1 2027IND-Enabling Studies Completion50% success